DOCSLIB.ORG

Metabolic Pathways of Steroids Department of Clinical Biochemistry, King’S College Hospital, London

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Metabolic Pathways of Steroids Department of Clinical Biochemistry, King’S College Hospital, London Metabolic Pathways of Steroids Department of Clinical Biochemistry, King’s College Hospital, London CH OH BILE 3 CH C O O H CH 2 C O O H CH 2 OH O O O 2 ACIDS CH C -O H -C HCOH + CH -C -O H 3 CH 3 CH C -S -C oA CH C - CH C -S -CoA 3 3 3 2 CH - CH2 CH C -S -C oA CH 2 CH O H OH ACETYL-COENZYME-A ACETOACETYL-COENZYME-A 2 2 O ISOPRENOID UNIT MEVALONIC ACID(3:5- SQUALENE HO HO FROM MAVALONIC ACID LANOSTEROL H ZYMOSTEROL DESMOSTEROL HO MONO-COENZYME A ESTER DIHYDROXY-3-METHYL H HO HO OF 3-HYDROXY-3-METHYL PENTANOIC ACID) CH3 CHOLESTEROL ( ANDROSTENEDIOL GLUTARIC ACID SO4) 20 α-HSD CH3 20,22-lyase HO (∆A2 17 α) 17 α-HSD ANDROSTENEDIOL-17 β CH HCOH PRENENETRIOL( ∆P3) CH 3 CH 3 CO 3 17 β-HSD HCOH O O CO 20 α-HSD CO OH OH OH 16 α-OHase CH 17-OHase 3 HO 17,20-lyase CH3 CH 3β-HSD/ ∆4,5isomerase 3 PREGNENEDIOL( ∆P2) HO HO HCOH O CO O 16 α-HYDROXY- ( SO ) HO HO 16 α-HYDROXYDEHYDRO- 20 α-DIHYDRO- PREGNENOLONE 4 PROGESTERONE CO 17 α-HYDROXY- EPIANDROSTERONE PROGESTERONE CH3 CH ( DEHYDRO- 20 α-HSD 3 PRENENOLONE ( ) O 16 α-OHase SO4 EPIANDROSTERONE (SO ) (16 α-DHA) 20 α-HSD O O 4 3α-HSD/ CO HCOH 5β-reductase OH OH HO HO 3α-HSD H CH 3αHSD/ CH 3 20 α-HSD 3 H CH OH 21-OHase 5β-reductase 17,20-lyase 2 CH O 3β-HSD/ ∆4,5isomerase PREGNANOLONE 3 17-OHase HO HO CO PROGESTERONE CH3 O PREGNANEDIOL HCOH HO HO H H CO DEHYDROEPI- CO 11 β-OHase H H AETIOCHOLANOLONE ANDROSTERONE (DHA) OH CO 17 α-HYDROXY- 5β-ANDROSTANEDIONE 5β-reductase 20 α-HSD OH PREGNANOLONE PREGNANETRIOL 17 β-HSD HO CH HO 3 H O 17,20-lyase 3β-HSD/ ∆4,5isomerase H OH O OH 11 β-HYDROXY- CH O 21-OHase 6β-HSD 3 CH OH O CO 6α-HYDROXY- DEOXYCORTICOSTERONE PROGESTERONE CH OH CH OH 2 6α-HYDROXY- 17 α-OHase 17 α-HYDROXY 2 2 PREGNANOLONE OH PREGNANEDIOL CO PROGESTERONE O HCOH 3α-HSD/ HO CO CO OH 5α-reductase 5β-reductase OH OH OH OH 3α-HSD/ 5β-reductase HO 11 β-OHase CH OH 20 α-HSD O 2 11 β-OHase HO O O 21-OHase O ANDROSTENEDIONE HO HO H 6-OXOPREGNANOLONE CO 21- DEOXYCORTISOL O CH3 H H ANDROSTENETRIOL 11-DEOXYCORTISOL (∆A3) CH2OH TERTRAHYDRO 'S' HEXAHYDRO 'S' 5α-ANDROSTANEDIONE 11 β-OHase CO 11 β-HSD (SUBSTANCE S) O 3α-HSD/ 19 -OHase CH OH OH 5β-reductase CO 17 β-HSD CH OH CH OH 2 OH 2 2 HO 3α-HSD CH 3 OH CH OH CO CO 2 O CO HO CH OH OH HCO CO CH2OH O O HO H HOCH O OH Aldosterone synthase O HO HO OH TETRAHYDRO- HO OH 11 β-HSD CO O DEOXY- 21- DEOXYCORTISONE O OH HO OH CORTICOSTERONE CORTISOL 11 β-HSD O OH 3α-HSD/ (COMPOUND F) 20 β-HSD O CH OH CH3 O 2 5β-reductase ALDOSTERONE O CORTICOSTERONE HO 5β-reductase O HO O O (hemi-acetal form) ALDOSTERONE (COMPOUND B) CO CO H O O H H OO 19-HYDROXY- 3α-HSD/ 3β-HSD/ O 16 α-HYDROXY- O HO 21-DEOXYTETRA- 20 β-DIHYDRO- 11 β-HYDROXY- ANDROSTENEDIONE 5α-reductase 5β-reductase O CORTISONE ANDROSTERONE ANDROSTENEDIONE TESTOSTERONE HYDROCORTISOL CORTISONE 5β-ANDROSTANOLONE TESTOSTERONE CH2OH CH OH CH OH 2 CH OH 3α-HSD/ 2 3α-HSD/ 6β-OHase 20 β-HSD 2 (COMPOUND 'E') 3α-HSD/ CH OH 5α-reductase 19 -OHase CO 5β-reductase 5α-reductase 2 aromatase CO CO 5β-reductase 3α-HSD HCO CH OH HO HO 2 HOCH CH2OH HCO HO HCO HO CO OH HO O H OH 3α-HSD 3α-HSD/ OH OH OH O II-DEHYDROCORTICOSTERONE 21-DEOXYTETRA- CO 5β-reductase CO 5α-reductase OH (COMPOUND A) HYDROCORTISONE HO OH OH O OH OH 3α-HSD/ HO 3α-HSD/ 5α-reductase 20 α-HSD H HO HO 5β-reductase O H H HO HO 5α-TETRAHYDRO- HO O O TETRAHYDRO- 3β-TETRAHYDRO- H H H ALDOSTERONE 20 β-DIHYDRO- HO ALDOSTERONE ALDOSTERONE O 19-HYDROXY- CORTISOL H 5β-ANDROSTANE- CH OH CH3 OH 5α-TETRAHYDROCORTISONE 5α-ANDROSTANOLONE OESTRIOL CH OH CH OH CH OH 2 TESTOSTERONE 2 2 2 TETRAHYDROCORTISONE 3α, 17 β-DIOL (DIHYDROTESTOSTERONE) HCOH 6β-HYDROXY- 3α-HSD/ aromatase CO O CORTISOL 3α-HSD/ CO CO CO 20 β-HSD O HO 5α-reductase 5β-reductase 20 α-HSD 20 α-HSD 20 β-HSD HO HO O 3α-HSD CH2OH CH2OH CH2OH CH2OH CH2OH CH2OH aromatase 17 β-HSD HO CO HOCH OH HO CO HCOH HOCH HCOH HO H HO HO HO H HO OH O O H H H OH O OH O O OH O 20 β-HSD OH OH allo-TETRAHYDRO 'B' TETRAHYDRO 'B' TETRAHYDRO 'A' 5α-TETRAHYDRO 'A' 11-OXO-PREGNANETRIOL 16α−ΟΗ ase OH HO HO HO HO 20 β-HSD H HO HO HO H HO 20 β-HSD H H H TETRAHYDROCORTISOL H H HO CH OH 5α-TETRAHYDRO α− CORTOLONE 5α-ANDROSTANE- OESTRONE CH OH 2 β-CORTOLONE 16 α-HYDROXY- 2 CORTISOL 5α-CORTOLONE 20 β-5 α-CORTOLONE 3α, 17 β-DIOL CH2OH OESTRONE HOCH 20 β-HSD HOCH 20 α-HSD 17,20-lyase 17 β-HSD HOCH HO HO 17,20-lyase 17,20-lyase 17,20-lyase HCO 20 α-HSD 20 β-HSD HO OH CH2OH O OH CH OH CH2OH O O CH OH 2 O 2 O HOCH OH HO HCOH HO HO HOCH HO H HCOH HO OH H HO HO HO H OH OH HEXAHYDRO 'B' HO HEXAHYDROALDOSTERONE 5a-HEXAHYDRO 'B' 17 β-HSD HO HO HO HO HO H 16 β-HYDROXY- EPI-OESTRIOL H OESTRADIOL-17 β KEY 11-OXO-ANDROSTERONE OESTRONE HO H HO HOO 11-OXO-AETIOCHOLANOLONE HO H H Catabolic pathways H 20 β, 5 α-CORTOL α− CORTOL 5α-CORTOL β-CORTOL 3α-HSD/ 5α-reductase Anabolic pathways 17,20-lyase 17,20-lyase 17,20-lyase 17,20-lyase O O O 11 β-HSD HO O Major hormonal steroids HO O Major urinary metabolites HO H OH H 11-OXO-ANDROSTENEDIONE 11 β-HYDROXY- ANDROSTERONE 11 β-HYDROXY- Intermediates AETIOCHOLANOLONE 3α-HSD/ 3α-HSD/ 5α-reductase 5β-reductase Credits Produced by Stephanie Wright based on a chart published circa 1970 by GLAXO LABORATORIES LTD with editing by Norman Taylor, from an initial idea by Kristine Moore. 1.
Load more

Recommended publications
  • Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes
    Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes May 2013 Authors Mark Ferrey Contributors/acknowledgements The MPCA is reducing printing and mailing costs This report contains the results of a study that by using the Internet to distribute reports and characterizes the presence of unregulated information to wider audience. Visit our website contaminants in Minnesota’s lakes. The study for more information. was made possible through funding by the MPCA reports are printed on 100 percent post- Minnesota Clean Water Fund and by funding by consumer recycled content paper manufactured the U.S. Environmental Protection Agency without chlorine or chlorine derivatives. (EPA), which facilitated the sampling of lakes for this study. The Minnesota Pollution Control Agency (MPCA) thanks the following for assistance and advice in designing and carrying out this study: Steve Heiskary, Pam Anderson, Dereck Richter, Lee Engel, Amy Garcia, Will Long, Jesse Anderson, Ben Larson, and Kelly O’Hara for the long hours of sampling for this study. Cynthia Tomey, Kirsten Anderson, and Richard Grace of Axys Analytical Labs for the expert help in developing the list of analytes for this study and logistics to make it a success. Minnesota Pollution Control Agency 520 Lafayette Road North | Saint Paul, MN 55155-4194 | www.pca.state.mn.us | 651-296-6300 Toll free 800-657-3864 | TTY 651-282-5332 This report is available in alternative formats upon request, and online at www.pca.state.mn.us. Document number: tdr-g1-16 Contents Contents ...........................................................................................................................................
    [Show full text]
  • Pharmaceutical and Veterinary Compounds and Metabolites
    PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer [email protected] LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep
    USOO6284263B1 (12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep. 4, 2001 (54) BUCCAL DRUG ADMINISTRATION IN THE 4,755,386 7/1988 Hsiao et al. TREATMENT OF FEMALE SEXUAL 4,764,378 8/1988 Keith et al.. DYSFUNCTION 4,877,774 10/1989 Pitha et al.. 5,135,752 8/1992 Snipes. 5,190,967 3/1993 Riley. (76) Inventor: Virgil A. Place, P.O. Box 44555-10 5,346,701 9/1994 Heiber et al. Ala Kahua, Kawaihae, HI (US) 96743 5,516,523 5/1996 Heiber et al. 5,543,154 8/1996 Rork et al. ........................ 424/133.1 (*) Notice: Subject to any disclaimer, the term of this 5,639,743 6/1997 Kaswan et al. patent is extended or adjusted under 35 6,180,682 1/2001 Place. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/626,772 Primary Examiner Thurman K. Page ASSistant Examiner-Rachel M. Bennett (22) Filed: Jul. 27, 2000 (74) Attorney, Agent, or Firm-Dianne E. Reed; Reed & Related U.S. Application Data ASSciates (62) Division of application No. 09/237,713, filed on Jan. 26, (57) ABSTRACT 1999, now Pat. No. 6,117,446. A buccal dosage unit is provided for administering a com (51) Int. Cl. ............................. A61F 13/02; A61 K9/20; bination of Steroidal active agents to a female individual. A61K 47/30 The novel buccal drug delivery Systems may be used in (52) U.S. Cl. .......................... 424/435; 424/434; 424/464; female hormone replacement therapy, in female 514/772.3 contraception, to treat female Sexual dysfunction, and to treat or prevent a variety of conditions and disorders which (58) Field of Search ....................................
    [Show full text]
  • Conjugated and Unconjugated Plasma Androgens in Normal Children
    Pediat. Res. 6: 111-118 (1972) Androstcncdionc sexual development dehydroepiandrosterone testosterone Conjugated and Unconjugated Plasma Androgens in Normal Children DONALD A. BOON,'291 RAYMOND E. KEENAN, W. ROY SLAUNWHITE, JR., AND THOMAS ACETO, JR. Children's Hospital, Medical Foundation of Buffalo, Roswell Park Memorial Institute, and Departments of Biochemistry and Pediatrics, School of Medicine, State University of New York at Buffalo, Buffalo, New York, USA Extract Methods developed in this laboratory permit measurement of the androgens, testos- terone (T), dehydroepiandrosterone (D), and androstenedione (A) on a 10-ml sample of plasma. We have determined concentrations of the unconjugated androgens (T, A, D) as well as of the sulfates of dehydroepiandrosterone (DS) and androsterone (AS) in the plasma of 85 healthy children of both sexes from birth through the age of 20 years. Our results are shown and summarized, along with those of other investigators. Mean plasma concentrations Sex and age ng/100 ml Mg/100 ml T A D AS DS Male Neonates 39 24 30 None detectable None detectable 1-8 years 25 58 64 2 11 9-20 years 231 138 237 28 74 Female Neonates 36 30 83 None detectable None detectable 1-8 years 11 69 54 5 20 9-20 years 28 84 164 22 44 Testosterone was elevated in both sexes in the newborn as compared with the 1-8- year-old group. In contrast, sulfated androgens, with one exception, were undetectable early in life. In males, there was a marked rise in all androgens, especially T, in the 9-18-year-old group.
    [Show full text]
  • Reduced Progesterone Metabolites in Human Late Pregnancy
    Physiol. Res. 60: 225-241, 2011 https://doi.org/10.33549/physiolres.932077 REVIEW Reduced Progesterone Metabolites in Human Late Pregnancy M. HILL1,2, A. PAŘÍZEK2, R. KANCHEVA1, J. E. JIRÁSEK3 1,2Institute of Endocrinology, Prague, Czech Republic, 2Department of Obstetrics and Gynecology of the First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic, 3Department of Clinical Biochemistry and Laboratory Diagnostics of the First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic Received November 20, 2010 Accepted November 25, 2010 On-line November 29, 2010 Summary Corresponding author In this review, we focused on the intersection between steroid A. Pařízek, Department of Obstetrics and Gynecology of the metabolomics, obstetrics and steroid neurophysiology to give a First Faculty of Medicine and General Teaching Hospital, comprehensive insight into the role of sex hormones and Apolinářská 18, 128 51 Prague 2, Czech Republic. E-mail: neuroactive steroids (NAS) in the mechanism controlling [email protected] pregnancy sustaining. The data in the literature including our studies show that there is a complex mechanism providing synthesis of either pregnancy sustaining or parturition provoking Introduction steroids. This mechanism includes the boosting placental synthesis of CRH with approaching parturition inducing the Although the effects of neuroactive and excessive synthesis of 3β-hydroxy-5-ene steroid sulfates serving neuroprotective 5α/β-reduced progesterone metabolites primarily as precursors for placental synthesis of progestogens, were extensively studied, the physiological relevance of estrogens and NAS. The distribution and changing activities of these substances remains frequently uncertain due to the placental oxidoreductases are responsible for the activation or lack of metabolomic data.
    [Show full text]
  • DATA SHEET 1. REANDRON® 1000 (1000 Mg/4 Ml Solution for Injection)
    DATA SHEET 1. REANDRON® 1000 (1000 mg/4 mL solution for injection) Reandron 1000, 1000 mg/ 4 mL solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ampoule/vial contains 1000 mg testosterone undecanoate (equivalent to 631.5 mg testosterone) in a 4 mL solution for injection (250 mg testosterone undecanoate/mL). Each mL solution for injection contains 250 mg testosterone undecanoate corresponding to 157.9 mg testosterone. For a full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM Reandron 1000 is a clear, colourless to yellowish-brown oily solution for injection. Testosterone undecanoate is a white or off-white crystalline substance. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Testosterone replacement in primary and secondary male hypogonadism. 4.2 Dose and method of administration 4.2.1 Dose Reandron 1000 (1 ampoule/vial equivalent to 1000 mg testosterone undecanoate) is injected every 10 to 14 weeks for testosterone replacement, where testosterone deficiency has been confirmed by clinical features and biochemical tests. Injections with this frequency are capable of maintaining sufficient testosterone levels and do not lead to accumulation. 4.2.1.1 Start of Treatment Serum testosterone levels should be measured before start of treatment and during initiation of treatment. Depending on serum testosterone levels and clinical symptoms, the first injection interval may be reduced to a minimum of 6 weeks as compared to the recommended range of 10 to 14 weeks for maintenance. With this loading dose, sufficient steady-state testosterone levels may be achieved more rapidly. 4.2.1.2 Individualisation of Treatment The injection interval should remain within the recommended range of 10 to 14 weeks.
    [Show full text]
  • Documentation, Codebook, and Frequencies
    Documentation, Codebook, and Frequencies Surplus Sera Laboratory Component: Racial/Ethnic Variation In Sex Steroid Hormone Concentrations Across Age In US Men Survey Years: 1988 to 1991 SAS Export File: SSHORMON.XPT First Published: October 2006 Last revised: N/A NHANES III Data Documentation Laboratory Assessment: Racial/Ethnic Variation in Sex Steroid Hormone Concentrations Across Age In US Men (NHANES III Surplus Sera) Years of Coverage: 1988-1991 First Published: October 2006 Last Revised: N/A Introduction It has been proposed that racial/ethnic variation in prostate cancer incidence may be, in part, due to racial/ethnic variation in sex steroid hormone levels. However, it remains unclear whether in the US population circulating concentrations of sex steroid hormones vary by race/ethnicity. To address this, concentrations of testosterone, sex hormone binding globulin, androstanediol glucuronide (a metabolite of dihydrotestosterone) and estradiol were measured in stored serum specimens from men examined in the morning sample of the first phase of NHANES III (1988-1991). This data file contains results of the testing of 1637 males age 12 or more years who participated in the morning examination of phase 1 of NHANES III and for whom serum was still available in the repository. Data Documentation for each of these four components is given in sections below. I. Testosterone Component Summary Description The androgen testosterone (17β -hydroxyandrostenone) has a molecular weight of 288 daltons. In men, testosterone is synthesized almost exclusively by the Leydig cells of the testes. The secretion of testosterone is regulated by luteinizing hormone (LH), and is subject to negative feedback via the pituitary and hypothalamus.
    [Show full text]
  • Steroid Secretion. Newly Discovered Functions in the Brain
    Steroid secretion. Newly Discovered Functions in the Brain. Fundamental and Clinical considerations. Bernardo O. Dubrovsky McGill University Medical School Montreal, Quebec, Canada B.O. Dubrovsky, 3445 Drummond Street, #701, Montreal, Quebec, H3G 1X9,Canada. Tel: (514) 844-5702 Fax: (514) 398-4370 E-mail: [email protected] Abstract While the relationships between endocrines and psychiatry have long been established, the implications of neurosteroid (NS) hormones, identified in the early 1980s for psychopathology, started to be recognized in the nineties. Tetrahydro metabolites of progesterone (ATHP) and deoxycorticosterone (ATHDOC) act as positive allosteric modulators of neurotransmitter receptors such as GABAA. Other NSs, i.e., androsterone, pregnenolone, dehydroepiandrosterone (DHEA), their sulfates and lipid derivatives modulate glycine-activated chloride channels, neural nicotinic acetylcholine receptors constituted in Xenopus laevis oocytes, and voltage-activated calcium channels. Sigma receptors, as pharmacologically defined by their effect on N-methyl-D- aspartate (NMDA) activity, have been studied in rat hippocampal preparations: here DHEAS acts as a sigma receptor agonist, differently from pregnenolone which appears as a sigma inverse agonist and progesterone which behaves as an antagonist. All of them were identified as NSs. Neuroactive steroids rapidly change CNS excitability and produce behavioral effects within seconds to minutes following administration to both laboratory animals and man. These fast actions probably indicate membrane mediated effects. This notwithstanding, Rupprecht et al. showed that after oxidation, ring A reduced pregnanes can regulate gene expression via the progesterone intracellular receptor. The necessary enzymes for the metabolism of primary adrenal and gonadal steroids, a peripheral source for NSs, exist in the brain in a compartmentalized way.
    [Show full text]
  • Pros and Cons Controversy on Molecular Imaging and Dynamic
    Open Access Archives of Biotechnology and Biomedicine Research Article Pros and Cons Controversy on Molecular Imaging and Dynamics of Double- ISSN Standard DNA/RNA of Human Preserving 2639-6777 Stem Cells-Binding Nano Molecules with Androgens/Anabolic Steroids (AAS) or Testosterone Derivatives through Tracking of Helium-4 Nucleus (Alpha Particle) Using Synchrotron Radiation Alireza Heidari* Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA *Address for Correspondence: Dr. Alireza Abstract Heidari, Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, In the current study, we have investigated pros and cons controversy on molecular imaging and dynamics USA, Email: of double-standard DNA/RNA of human preserving stem cells-binding Nano molecules with Androgens/ [email protected]; Anabolic Steroids (AAS) or Testosterone derivatives through tracking of Helium-4 nucleus (Alpha particle) using [email protected] synchrotron radiation. In this regard, the enzymatic oxidation of double-standard DNA/RNA of human preserving Submitted: 31 October 2017 stem cells-binding Nano molecules by haem peroxidases (or heme peroxidases) such as Horseradish Peroxidase Approved: 13 November 2017 (HPR), Chloroperoxidase (CPO), Lactoperoxidase (LPO) and Lignin Peroxidase (LiP) is an important process from Published: 15 November 2017 both the synthetic and mechanistic point of view. Copyright: 2017 Heidari A. This is an open access article distributed under the Creative
    [Show full text]
  • ANDROGEN ELITE (Dried Urine)
    ANDROGEN ELITE (dried urine) The aging male experiences a decrease in testosterone at a rate of 10% per decade from the age of 30. This reduction of testosterone and other androgens experienced as a consequence of the aging process has been named andropause or androgen deficiency of the aging male (ADAM). Symptoms associated with ADAM can be associated with impaired 5-alpha reductase or aromatase activity, enzymes responsible for conversion of Testosterone to Dihydrotestosterone (DHT) or estrogens. Symptoms of ADAM consist of somatic, sexual and psychological changes including reduced muscle mass, reduced BMD, increased cardiovascular disease, lowered libido, depression, increased Alzheimer’s disease and a general decrease in well-being. This test provides a focused overview of the male, some female hormones, and its metabolites: Estradiol, Estrone, Estriol, 2OHE1, 16αOHE1; Pregnanediol, Allopregnanolone, Testosterone, Epi- Testosterone, 5α-dihydrotestosterone, Androstenedione, DHEA, 5α,3α- Androstanediol, Cortisol, Cortisone, Tetrahydrocortisol, Tetrahydrocortisone. Hormones and Aging Hormones are powerful molecules that are essential for life. Imbalances of hormones affects other organ systems like the adrenals, thyroid and nervous system. What many people fail to recognise however, is that partial deficiencies also have a wide reaching negative effect on the human body. This is understandable however, when a hormone’s mechanism of action is understood. Aging is one process which is associated with hormone decline. In the past it was thought that this reduction was a normal consequence of the aging process. However, more recently an alternative theory has been proposed; that hormones do not decrease because we age, but rather we age because our hormones decrease i.e.
    [Show full text]
  • Prescribing Testosterone and DHEA: the Role of Androgens in Women
    CURRENT DRUG THERAPY CME MOC Taryn Smith, MD, NCMP Pelin Batur, MD, FACP, NCMP Section of Women’s Health, Division of Department of Subspecialty Women’s Health, Ob/Gyn & General Internal Medicine, Mayo Clinic, Women’s Health Institute, Cleveland Clinic; Associate Jacksonville, FL Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Deputy Editor, Cleveland Clinic Journal of Medicine Prescribing testosterone and DHEA: The role of androgens in women ABSTRACT strogens are the principal sex hormones E responsible for female reproductive matu- In women, the androgens testosterone and dehydroepi- ration and sexual characteristics. However, androsterone (DHEA) play important physiologic roles in androgens are also important for female sexual reproductive tissues, mood, cognition, the breast, bone, health and well-being.1 The physiologic ef- muscle, vasculature, and other systems. This article re- fects of androgens are in part due to their role views the effects of androgens in women, as well as the as precursors for estrogen synthesis, but these indications and best-practice recommendations for the hormones also have independent effects on use of androgen therapy. female reproductive tissues, mood, cognition, breasts, bones, muscles, vasculature, and other systems.1 ■ KEY POINTS Currently, the only evidenced-based indication for testos- See related editorial, page 44 terone therapy in women is for treating hypoactive sexual Here we will discuss the physiologic roles desire disorder in postmenopausal women. Several ran- of androgens as well as the indications and domized controlled trials have established the short-term best-practice recommendations for androgen safety and effi cacy of prescribed testosterone in women therapy in women.
    [Show full text]
  • Hormonal Profile of Menopausal Women Receiving
    Journal of Endocrinological Investigation https://doi.org/10.1007/s40618-020-01192-x REVIEW Hormonal profle of menopausal women receiving androgen replacement therapy: a meta‑analysis L. Marina1 · A. S. Sojat1 · E. Maseroli2 · G. Spaggiari3,4 · S. Pandurevic1 · D. Santi3,4 Received: 14 November 2019 / Accepted: 27 January 2020 © Italian Society of Endocrinology (SIE) 2020 Abstract Purpose Ovarian and adrenal aging leads to a progressive decline in androgen levels and deleterious efects on the quality of life. Despite this, specifc replacement is not routinely recommended in the management of women with a physiological or pathological decline in their production, mainly due to the lack of long-term follow-up safety data. The purpose of this paper was to meta-analyze and summarize the existing data about hormonal profle changes in menopausal women receiving androgen replacement treatments. Full-text articles published through May 30, 2018 were found via MEDLINE and Embase and selected according to the strict inclusion criteria. Methods Randomized clinical trials and case–control studies were enrolled. Studies not reporting steroid serum levels or not providing a control group were excluded from the analysis. Studies enrolling women with genetic defects or severe chronic systemic diseases were excluded. 113 papers fulflled the inclusion criteria and 56 papers were included in the analysis. Desired data were compiled and extracted by independent observers. Results Androgen administration increases E1, E2, testosterone, DHEA and DHEAS serum levels, and reduces SHBG. However, the E1 and E2 increase is evident only when DHEA is administered. Conclusions Whatever androgen formulation we choose in postmenopausal women, the end result is a rise in testosterone serum levels.
    [Show full text]